What are the clinical practice points to translate asthma management recommendations into actionable bedside decisions, treatment protocols, and clinical algorithms?

Clinical Practice Points for Asthma Management

Age-Stratified Stepwise Treatment Algorithm

Use age-specific treatment pathways as your primary decision framework: ages 0-4 years, 5-11 years, and ≥12 years each require distinct algorithms 1. The stepwise approach forms the backbone of bedside decision-making, with treatment escalation or de-escalation based on control status assessed every 3 months.

Initial Treatment Selection

For treatment-naive patients, assess both impairment (symptom frequency, nighttime awakenings, rescue medication use, activity limitation) and risk (exacerbation history, lung function, exposure to triggers) to select the appropriate starting step 1.

Key decision point: Never initiate or continue SABA-only treatment for long-term asthma management 2, 3. This represents a critical shift from historical practice.

Preferred vs. Alternative Options Within Each Step

• Preferred options = treatments with strongest evidence support
• Alternative options = acceptable if preferred unavailable, cost-prohibitive, or patient already controlled on them
• When alternatives fail, switch to preferred treatment within the same step before stepping up 1

Anti-Inflammatory Reliever (AIR) Strategy

For adults and adolescents, prioritize low-dose ICS-formoterol as anti-inflammatory reliever therapy (either as-needed-only or as maintenance-and-reliever therapy) over traditional SABA-based regimens 3. This approach substantially reduces severe exacerbations and simplifies treatment.

AIR Implementation:

• As-needed only (AIR-only): For mild intermittent asthma
• Maintenance + reliever (MART): For persistent asthma requiring daily controller
• Both strategies superior to SABA reliever with separate ICS maintenance 2, 3

Treatment Adjustment Protocol

Step Up Criteria:

• Uncontrolled symptoms despite 3 months of current therapy
• ≥2 exacerbations requiring oral corticosteroids in past year
• Any life-threatening exacerbation
• Progressive lung function decline

Step Down Criteria:

• Well-controlled asthma for ≥3 consecutive months
• No exacerbations during control period
• Lung function stable or improved
• Patient demonstrates good inhaler technique and adherence

Critical caveat: Assess and optimize adherence, inhaler technique, trigger avoidance, and comorbidities before stepping up 1.

Control Assessment Framework

Define control as the complete absence of 4:

• Daytime or nighttime symptoms
• Activity limitation
• Need for rescue medication (beyond AIR in MART regimens)
• Exacerbations
• Oral corticosteroid use

Plus optimization of lung function to patient's personal best.

Assessment Timing:

• Every clinical visit: Symptom control, inhaler technique, adherence
• Every 3 months minimum: Lung function (spirometry)
• Before treatment changes: Type 2 biomarkers (blood eosinophils, FeNO if available)
• Annually: Exacerbation risk factors, comorbidities, patient goals

Phenotyping for Treatment Selection

Type 2 Inflammation Indicators:

• Blood eosinophils ≥300 cells/μL (or ≥150 with recurrent exacerbations)
• FeNO ≥25 ppb (adults) or ≥20 ppb (children)
• Allergic triggers with positive specific IgE
• Late-onset asthma with nasal polyps

Clinical application: Type 2 biomarkers guide ICS responsiveness prediction and biologic selection in severe asthma 1, 3.

Severe Asthma Management Algorithm

Step 1: Verify Diagnosis

• Confirm variable expiratory airflow limitation with objective testing
• Rule out asthma mimics (vocal cord dysfunction, COPD, bronchiectasis, cardiac disease)

Step 2: Optimize Modifiable Factors

• Correct inhaler technique (observed demonstration)
• Confirm adherence (prescription refill data, inhaler counters)
• Eliminate trigger exposures (smoking, occupational, allergens)
• Treat comorbidities (rhinosinusitis, GERD, obesity, anxiety/depression)
• Minimize systemic corticosteroid exposure

Step 3: Maximize Conventional Therapy

• High-dose ICS-LABA (maintenance)
• Add LAMA (tiotropium) for additional bronchodilation 2
• Consider maintenance oral corticosteroids only if biologics unavailable/failed

Step 4: Phenotype and Select Biologic

For allergic asthma (elevated IgE, positive aeroallergen testing):

• Omalizumab (anti-IgE) 2, 5

For eosinophilic asthma (blood eosinophils ≥300 cells/μL):

• Mepolizumab, benralizumab, or reslizumab (anti-IL-5 pathway) 2, 5
• Dupilumab (anti-IL-4Rα) - also effective with lower eosinophil thresholds 5

For oral corticosteroid-dependent asthma:

• Prioritize biologics with proven OCS-sparing effects 5

For comorbid chronic rhinosinusitis with nasal polyps:

• Dupilumab preferred 5

Step 5: Assess Biologic Response

• Evaluate at 4 months minimum
• Criteria: reduced exacerbations, improved lung function, reduced OCS need, improved quality of life
• If inadequate response: verify adherence to biologic, reassess phenotype, consider switching biologic class 5

Acute Exacerbation Protocol

Immediate Treatment:

1. Oxygen to maintain SpO₂ ≥90% (≥95% in children)
2. High-dose SABA via nebulizer or MDI with spacer (4-10 puffs every 20 minutes × 3 doses)
3. Systemic corticosteroids (prednisone 40-50 mg or equivalent) within 1 hour
4. Ipratropium bromide added to SABA for severe exacerbations

Disposition Decision:

• Discharge criteria: PEFR or FEV₁ >70% predicted, SpO₂ >90%, sustained response ≥60 minutes after last treatment
• Admit criteria: PEFR or FEV₁ <40% predicted, no improvement after initial treatment, altered mental status, prior ICU admission for asthma

Post-Exacerbation Management (Critical):

• Schedule follow-up within 1-7 days
• Reassess and adjust long-term controller therapy (usually step up)
• Provide/review written asthma action plan
• Verify inhaler technique
• Address triggers that precipitated exacerbation 3

Common Pitfalls to Avoid

1. Continuing SABA-only treatment in persistent asthma - always add ICS-containing therapy 2, 3
2. Stepping up before optimizing current step - verify technique, adherence, trigger control first 1
3. Using alternative treatments when preferred options fail - switch to preferred within same step before escalating 1
4. Delaying step-down in well-controlled patients - reassess every 3 months for de-escalation opportunity 1
5. Selecting biologics without phenotyping - always measure Type 2 biomarkers before biologic initiation 5
6. Inadequate post-exacerbation follow-up - this is when treatment intensification prevents future events 3

Patient Self-Management Integration

Provide written asthma action plans specifying:

• Daily controller medications with specific doses and devices
• How to recognize worsening (symptom-based and peak flow-based zones)
• Exact steps for increasing treatment (green/yellow/red zone actions)
• When to seek emergency care
• Follow-up appointment schedule

Action plans reduce exacerbations and hospitalizations when combined with regular provider review 6.